Aytu BioPharma Announces Publication of In Vitro Study Demonstrating That Ultraviolet-A Light Increases Mitochondrial Anti-Viral Signaling Protein Within Cells
ACCESSWIRE
13 May 2021, 00:55 GMT+10
ENGLEWOOD, CO / ACCESSWIRE / May 12, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that
in vitro data related to the ultraviolet (UV) A light used in the Healight™ UVA endotracheal catheter technology was published in BioRxiv, an online archive for health science manuscripts that are not yet peer reviewed.
The manuscript titled
Ultraviolet-A light increases mitochondrial anti-viral signaling protein via cell-cell communication concluded that UVA light increases the expression of mitochondrial antiviral-signaling (MAVS) protein within cells, and the results suggest that this transmission of an increase in intracellular MAVS involves cell-to-cell communic
Aytu BioPharma to Report Third Quarter Fiscal 2021 Results on May 17, 2021
ACCESSWIRE
11 May 2021, 06:05 GMT+10
ENGLEWOOD, CO / ACCESSWIRE / May 10, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that it will host a conference call and live webcast on Monday, May 17, 2021, at 4:30 p.m. ET to report its financial results for the fiscal third quarter ended March 31, 2021 and review recent accomplishments.
Conference Call Information
201-689-8584 (international)
The webcast will be accessible live and archived at the following link https://www.webcaster4.com/Webcast/Page/2142/40724 and on Aytu BioPharma s website, within the Investors section under Events & Presentations, at
BOSTON, May 05, 2021 (GLOBE NEWSWIRE) Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with
Transformative, leading allogeneic NKT cell platform technology expands Athenex s cell therapy development capability
Platform has broad applications based on transducing NKT cells with chimeric antigen receptors (CARs) and T cell receptors (TCRs) to target hematological and solid cancers, respectively
Total potential consideration of $185 million, comprising $70 million upfront primarily in Athenex common stock, and $115 million in development milestones Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, led by its Orascovery platform, today announced that it has acquired Kuur Therapeutics, Inc., the leading developer of off-the-shelf CAR-NKT cell immunotherapies for the treatment of solid and hematological malignancies.
05/05/2021 | Press release | Distributed by Public on 05/05/2021 00:16
Kuur Therapeutics Ltd - Athenex to Acquire Kuur Therapeutics to expand cell therapy development with off-the-shelf engineered CAR-NKT platform
Transformative, leading allogeneic NKT cell platform technology expands Athenex s cell therapy development capability
Platform has broad applications based on transducing NKT cells with chimeric antigen receptors (CARs) and T cell receptors (TCRs) to target hematological and solid cancers, respectively
Total potential consideration of $185 million, comprising $70 million upfront primarily in Athenex common stock, and $115 million in development milestones
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, led by its Orascovery platform, today announced that it has acquired Kuur Therapeutics, Inc., the leading developer of